These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22162533)

  • 1. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease.
    Knebel W; Rao N; Uchimura T; Mori A; Fisher J; Gastonguay MR; Chaikin P
    J Clin Pharmacol; 2012 Oct; 52(10):1468-81. PubMed ID: 22162533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
    Müller T
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease.
    Knebel W; Rao N; Uchimura T; Mori A; Fisher J; Gastonguay MR; Chaikin P
    J Clin Pharmacol; 2011 Jan; 51(1):40-52. PubMed ID: 20200269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
    Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
    Chen W; Wang H; Wei H; Gu S; Wei H
    J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of istradefylline for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Istradefylline for the treatment of Parkinson's disease.
    Park A; Stacy M
    Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
    Kondo T; Mizuno Y;
    Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
    Yabe I; Kitagawa M; Takahashi I; Matsushima M; Sasaki H
    Clin Neuropharmacol; 2017; 40(6):261-263. PubMed ID: 28976411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
    Mizuno Y; Hasegawa K; Kondo T; Kuno S; Yamamoto M;
    Mov Disord; 2010 Jul; 25(10):1437-43. PubMed ID: 20629136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
    Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
    Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of istradefylline for Parkinson's disease: A meta-analysis.
    Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
    Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects.
    Mukai M; Uchimura T; Zhang X; Greene D; Vergeire M; Cantillon M
    J Clin Pharmacol; 2018 Feb; 58(2):193-201. PubMed ID: 28881378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
    Mizuno Y; Kondo T;
    Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.